Is this you? Create Your Porfile
Avatar

Berthold Hocher

Solvay

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Berthold Hocher is active.

Explore More

Publication

Featured researches published by Berthold Hocher.

British Journal of Pharmacology | 2009

The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure.

Philipp Kalk; Eggert B; Katharina Relle; Michael Godes; Susi Heiden; Yuliya Sharkovska; Yvan Fischer; Dieter Ziegler; Bielenberg Gw; Berthold Hocher

Myocardial fibrosis is an unwanted effect associated with chronic renal failure. The adenosine system is involved in cardiac and renal function. Therefore, we investigated the novel selective adenosine A1 receptor antagonist SLV320 focusing on its potential in preventing cardiomyopathy in rats with 5/6 nephrectomy.

Archive | 2007

Use of adenosine a1 antagonists in radiocontrast media induced nephropathy

Berthold Hocher; Yvan Fischer; Klaus Witte; Dieter Ziegler

Archive | 2004

Method and pharmaceutical compositions for treating or inhibiting renal dysfunctions, diseases or disorders, particularly in diabetic patients

Dirk Thormaehlen; Berthold Hocher; Harald Waldeck

Journal of Cardiac Failure | 2008

Cardio-Renal Effects of the A1 Adenosine Receptor Antagonist SLV320 in Chronic Heart Failure Patients 10/2/08

Veselin Mitrovic; Petar Seferovic; Slobodan S. Dodic; Hanka Devoogd; Christiane Böcker; Dieter Ziegler; Michael Godes; Hans Essers; Berthold Hocher

Archive | 2013

Xanthinderivat als dpp-4-hemmer zur verwendung bei der behandlung von durch podozyten vermittelten erkrankungen und/oder des nephrotischen syndroms

Thomas Klein; Eynatten Maximilian Von; Berthold Hocher; Michael Mark; Yuliya Sharkovska

Archive | 2013

Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique

Thomas Klein; Eynatten Maximilian Von; Berthold Hocher; Michael Mark; Yuliya Sharkovska

Archive | 2010

Soluble guanylate cyclase stimulator riociguat reduces organ damage in experimental models of hypertension

Johannes-Peter Stasch; Yuliya Sharkovska; Philipp Kalk; Bettina Lawrenz; Michael Godes; Linda S. Hoffmann; Kathrin Wellkisch; Sandra Geschka; Katharina Relle; Berthold Hocher

Archive | 2008

PHARMACEUTICAL COMBINATION COMPRISING AN ADENOSINE A1 ANTAGONIST AND A RADIOCONTRAST MEDIA

Berthold Hocher; Yvan Fischer; Klaus Witte; Dieter Ziegler

Archive | 2007

***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***Method and pharmaceutical compositions for treating or inhibiting renal dysfunctions, diseases or disorders, particularly in diabetic patients

Dirk Thormaehlen; Berthold Hocher; Harald Waldeck

Archive | 2007

PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF RENAL DYSFUNCTION

Dirk Thormaehlen; Berthold Hocher; Harald Waldeck

Explore More

Collaboration

Dive into the Berthold Hocher's collaboration.

Top Co-Authors
Avatar

Dirk Thormaehlen

Solvay

View shared research outputs
Top Co-Authors
Avatar

Harald Waldeck

Solvay

View shared research outputs
Top Co-Authors
Avatar

Dieter Ziegler

Solvay

View shared research outputs
Top Co-Authors
Avatar

Yuliya Sharkovska

Charité

View shared research outputs
Top Co-Authors
Avatar

Michael Godes

Charité

View shared research outputs
Top Co-Authors
Avatar

Yvan Fischer

Solvay

View shared research outputs
Top Co-Authors
Avatar

Katharina Relle

Charité

View shared research outputs
Top Co-Authors
Avatar

Klaus Witte

Solvay

View shared research outputs
Top Co-Authors
Avatar

Philipp Kalk

Charité

View shared research outputs
Top Co-Authors
Avatar

Eynatten Maximilian Von

Boehringer Ingelheim

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge